InspireMD Inc Total Liabilities
InspireMD Inc total liabilities. Based on the latest financial reports, InspireMD Inc (NSPR) has total liabilities worth $3.48 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check InspireMD Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of InspireMD Inc (2008–2025)
Total liabilities of InspireMD Inc from 2008 to 2025. This chart illustrates how InspireMD Inc's total liabilities have evolved over time, based on quarterly financial data.
InspireMD Inc Competitors by Total Liabilities
The table below lists competitors of InspireMD Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hipay Group SA
PA:ALHYP
|
France | €182.54 Million |
|
Sypris Solutions Inc
NASDAQ:SYPR
|
USA | $91.40 Million |
|
Next Bt Co. Ltd
KQ:065170
|
Korea | ₩8.72 Billion |
|
Playside Studios Ltd
AU:PLY
|
Australia | AU$14.74 Million |
|
Atlantaa Limited
NSE:ATLANTAA
|
India | Rs3.52 Billion |
|
Edesa Biotech Inc
NASDAQ:EDSA
|
USA | $3.91 Million |
|
Commerce Resources Corp.
V:CCE
|
Canada | CA$2.58 Million |
|
Big Camera Corporation Public Company Limited
BK:BIG
|
Thailand | ฿1.09 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down InspireMD Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of InspireMD Inc.
Liquidity & Leverage Metrics
InspireMD Inc Total Liabilities Ratios Explained
InspireMD Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how InspireMD Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for InspireMD Inc (2008–2025)
The table below shows the annual total liabilities of InspireMD Inc from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $14.20 Million | +32.48% |
| 2024-12-31 | $10.72 Million | +31.68% |
| 2023-12-31 | $8.14 Million | +12.15% |
| 2022-12-31 | $7.26 Million | +17.48% |
| 2021-12-31 | $6.18 Million | +10.08% |
| 2020-12-31 | $5.61 Million | +24.84% |
| 2019-12-31 | $4.50 Million | +27.57% |
| 2018-12-31 | $3.52 Million | +4.29% |
| 2017-12-31 | $3.38 Million | -37.00% |
| 2016-12-31 | $5.37 Million | -38.50% |
| 2015-12-31 | $8.72 Million | -38.76% |
| 2014-12-31 | $14.25 Million | -7.05% |
| 2013-12-31 | $15.33 Million | +44.21% |
| 2012-12-31 | $10.63 Million | 0.00% |
| 2012-06-30 | $10.63 Million | 0.00% |
| 2011-12-31 | $10.63 Million | +128802.37% |
| 2010-12-31 | $8.24K | 0.00% |
| 2009-12-31 | $8.24K | +153.69% |
| 2008-12-31 | $3.25K | -- |
About InspireMD Inc
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard c… Read more